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Summary
 
The inflammatory response involves sequential adhesive interactions between cell adhesion
molecules of leukocytes and the endothelium. Unlike the several adhesive steps that precede it,
transendothelial migration (diapedesis), the step in which leukocytes migrate between apposed
endothelial cells, appears to involve primarily one adhesion molecule, platelet–endothelial cell
adhesion molecule (PECAM, CD31). Therefore, we have focused on PECAM as a target for
antiinflammatory therapy. We demonstrate that soluble chimeras made of the entire extracellu-
lar portion of PECAM, or of only the first immunoglobulin domain of PECAM, fused to the
Fc portion of IgG, block diapedesis in vitro and in vivo. Furthermore, the truncated form of
the PECAM-IgG chimera does not bind stably to its cellular ligand. This raises the possibility
of selective anti-PECAM therapies that would not have the untoward opsonic or cell-activat-
ing properties of antibodies directed against PECAM.
 
T
 
he emigration of leukocytes from the bloodstream into
a site of inflammation involves a series of interactions
between cell adhesion molecules (CAMs)
 
1
 
 on the leuko-
cyte and the venular endothelium. This phenomenon has
been dissected into discrete steps of rolling, activation, tight
adhesion, transmigration, and migration across the base-
ment membrane (1–4). If a relevant leukocyte or endothe-
lial CAM is inhibited, leukocytes do not proceed to the
next step. During transendothelial migration (TEM), the leu-
kocytes squeeze between tightly apposed endothelial cells.
This process involves the function of platelet–endothelial
cell adhesion molecule (PECAM, CD31), a member of the
immunoglobulin gene superfamily, which is expressed on
the surfaces of monocytes (Mo), granulocytes, NK cells,
some T cell subsets, and concentrated at the borders be-
tween endothelial cells (5–7).
In the presence of appropriate anti-PECAM mAbs, leu-
kocytes can bind tightly to endothelial monolayers and mi-
grate to the endothelial junctions, but they do not proceed
through the junctions (8, 9). This process is reversible since
diapedesis resumes shortly after removing the blocking mAb
(8). Transmigration appears to involve homophilic interac-
tion of PECAM on the leukocyte with PECAM on the en-
dothelial cell. Blocking the PECAM on either cell is suffi-
cient to maximally block TEM in vitro; blocking PECAM
on both cells has no additional effect (8).
Depending on the leukocyte type and the inflammatory
stimulus, more than one CAM can participate in each of
the steps of rolling, activation, and tight adhesion (1, 10).
Thus, it is difficult to block inflammation using individual
reagents directed at the particular molecules involved in
these steps. In contrast, PECAM mediates a common final
step in emigration for many leukocyte types activated by a
variety of stimuli. In addition, PECAM has no other known
function in vivo. Most of the other CAMs important in
emigration of leukocytes have other roles in the immune
system (1, 11), the blockade of which could lead to unto-
ward consequences.
Therefore, PECAM is an attractive target molecule for
antiinflammatory therapy. In fact, mAbs (12) and poly-
clonal antibodies (13–15) against PECAM block acute in-
flammation in response to a variety of stimuli. However,
xenogeneic mAb has the potential to opsonize leukocytes,
leading to leukopenia, as well as to stimulate production of
neutralizing antibodies by the host, making it a poor agent
for chronic therapy. Moreover, engagement of CAMs by
high affinity mAbs can activate cells, especially leukocytes.
Ligation of leukocyte PECAM by a variety of mAbs can
trigger an adhesion cascade resulting in the upregulation of
leukocyte integrin binding activity on T cells (16), PMN,
Mo (17), and NK cells (9, 18).
To avoid these potential problems, we fused portions of
the extracellular region of autologous PECAM to the hu-
 
1
 
Abbreviations used in this paper:
 
 CAM, cell adhesion molecule; HUVEC,
human umbilical vein endothelial cells; Mo, monocytes; PECAM, plate-
let–endothelial cell adhesion molecule, CD31; TEM, transendothelial mi-
gration.
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man Fc chain. These soluble chimeras competitively inhibit
TEM in vitro and in vivo. A chimera containing only PE-
CAM domain 1, which is incapable of binding stably to
cellular PECAM, blocks emigration of both PMN and
monocytes into the inflamed peritoneal cavity. This is the
first demonstration that a portion of a CAM with no stable
binding activity itself can block inflammation in vivo.
 
Materials and Methods
 
Cell Culture
 
Human umbilical vein endothelial cells (HUVEC) were iso-
lated from fresh umbilical veins and cultured in medium 199
(M199; GIBCO BRL, Gaithersburg, MD) 
 
1
 
 20% normal human
serum on hydrated collagen gels as described previously (5). Cells
were used at passage two. For experiments involving FACS
 
Ò
 
 (Bec-
ton Dickinson, San Jose, CA) analysis of chimeric proteins bear-
ing the human IgG Fc region, HUVEC were cultured in 20% fe-
tal bovine serum (LPS-free; Hyclone Labs., Logan, UT).
 
Monocyte-selective Transendothelial Migration Assay
 
The details of this assay have been previously published (8, 19).
Transendothelial migration was quantitated by Nomarski optics as
described previously (4, 8). In some experiments, transmigration
was also quantitated on cross sections of paraffin-embedded mono-
layers. These specimens were prepared by carefully removing rep-
licate sample monolayers and placing the endothelial surfaces
against each other with the collagen gel sides facing outward.
This avoided mechanical dislodgement of cells during the embed-
ding process. After substitution in wax, the specimens were bi-
sected so that cuts through the specimen produced cross sections
of four monolayer samples (two different portions of each of the
two monolayers). Quantitation was performed on three levels of
such specimens separated by at least 50 
 
m
 
m so that different areas
of the specimen would be sampled and the same cells would not
be counted twice.
 
Construction and Production of Chimeric Ig Fusion Proteins
 
Truncated Human PECAM-IgG.
 
Construction of the set of
human PECAM-IgG chimeras has been described previously (4).
The novel human PECAM-IgG chimera consisting of domains
3–6 was made using a similar PCR strategy. The sequences of the
primer pair used in generating the DNA fragment corresponding
to domains 3–6 were: 5
 
9
 
-TAG ATC 
 
GAT ATC
 
 GAA GGA
GCT CAG CTC-3
 
9
 
 and 5
 
9
 
-TAG AAT ATC 
 
GCG GCC GC
 
T
TTC TTC CAT-3
 
9
 
, with the EcoRV and NotI sequences indi-
cated in bold.
 
Murine PECAM-IgG Proteins.
 
A full-length soluble PECAM-
IgG cDNA was constructed by ligating the cDNA encoding the
extracellular portion of murine PECAM (20) with a cDNA en-
coding the human IgG1 Fc domain, in a similar fashion to the
construction of human PECAM-IgG (4). This was subcloned
into pcDNAI/neo (Invitrogen, San Diego, CA) at the SalI and XbaI
sites. A PCR cloning strategy similar to that used to make the hu-
man truncated PECAM-IgGs (4) was used to construct the murine
counterparts with the full-length PECAM-IgG cDNA used as the
template. The sequence of the 5
 
9
 
 PCR primer was 5
 
9
 
-TCA
G
 
AA GCT T
 
CC ACC ATG CTC CTG-3
 
9
 
. The HindIII re-
striction sequence is in bold; the initiation codon is underlined.
The sequence of the 3
 
9
 
 primer for producing the first domain of
murine PECAM was 5
 
9
 
-TAG AAT ATC 
 
GCG GCC GC
 
T
TCT GTC ACC TCC TT-3
 
9
 
. The NotI restriction site is in
bold.
 
CD14-IgG cDNA Fusion Plasmid.
 
The CD14-IgG cDNA fu-
sion plasmid was a gift of Dr. Henri Lichenstein (Amgen, Inc.,
Boulder, CO). The CD14-IgG insert (21) was retrieved from the
original pSPORT vector by XbaI and SalI digestions, blunt-
ended, and transferred to the EcoRV site of the selectable mam-
malian expression vector, pcDNAI/neo.
 
PECAM-IgM Fusion Plasmid.
 
Construction of the PECAM-IgM
fusion plasmid was based on a patented vector, pm2CD2IgM, gpt
(American Type Culture Collection accession No. 68280, pro-
vided by Dr. M.F. Concino of Procept, Inc., Cambridge, MA).
This vector contains the C
 
H
 
2 
 
1
 
 C
 
H
 
3 
 
1
 
 C
 
H
 
4 domains of human
IgM fused to the extracellular portion of CD2 (22). The IgM
portion was generated from the vector by PCR using the follow-
ing pair of frame-retaining oligonucleotide primers containing
NotI and XbaI restriction sequences: 5
 
9
 
-AAT ACA TAG A
 
GG
CCG CC
 
A GTG ATT GCT GAG CTG-3
 
9
 
 and 5
 
9
 
-GGG TT
 
T
CTA GA
 
A GCC ACT-3
 
9
 
. The NotI and XbaI restriction se-
quences, respectively, are printed in bold; the first five codons of
the IgM are underlined. PECAM-IgM constructs were made
from the corresponding PECAM-IgG pcDNAI/Neo vectors by
replacing the IgG portion with IgM cDNA at the NotI and XbaI
sites.
To produce soluble fusion proteins, L cell fibroblasts were sta-
bly transfected by electroporation (23) with cDNAs encoding each
of the constructs and selected in 0.5 mg/ml G418. Clones were
picked and transplanted to 96-well trays. Supernates from these
clones were tested by ELISA for expression of human IgG or
IgM. Positive clones were expanded, subcloned, and tested for
production of the appropriate PECAM domains by mAb-binding
ELISA (4), and for size by Western blotting.
Cultures were weaned to growth in 1.5% FCS and expanded
to roller bottle culture. Three to four liters of conditioned me-
dium from transfectant cultures were pooled. PECAM-IgG was pu-
rified by affinity chromatography on protein A–Sepharose; PECAM-
IgM was purified by affinity chromatography on hec7-Sepharose.
Proteins were eluted with 0.1 M glycine buffer, pH 2.5, neutral-
ized, and dialyzed against phosphate-buffered saline. When neces-
sary, purified protein was concentrated using centricon membranes
(Amicon, Beverly, MA). Chimeric proteins were filter sterilized.
All mAb and chimeric protein reagents used in these experiments
were free of detectable endotoxin (
 
,
 
0.1 endotoxin units) by lim-
ulus amebocyte lysate assay (BioWhittaker, Inc., Walkersville, MD).
 
FACS
 
Ò
 
 Analysis.
 
FACS
 
Ò
 
 analysis was performed with Con-
sort 30 software. Nonenzymatically resuspended HUVEC or freshly
isolated PBMC were incubated with mAb or PECAM-IgG chi-
meras on ice for 30 min, washed gently, and then incubated with
F(ab
 
9
 
)
 
2
 
 fragments of FITC-labeled rabbit anti–mouse IgG or
FITC-labeled goat anti–human IgG for 30 min on ice. Cells were
then washed and analyzed. At least 10,000 cells were collected for
each sample. PBMC were preincubated with mAb IV.3 and 3G8
(Medarex, Inc., Annandale, NJ) against Fc
 
g
 
R II and III, respec-
tively. Monocytes were selectively analyzed in the PBMC sam-
ples using appropriate forward- and side-scatter gates, which were
confirmed using monocyte-specific markers. Graphs were pro-
duced using WinList software for curve smoothing.
 
Thioglycollate Broth-induced Peritonitis.
 
These studies were per-
formed and analyzed as previously described (12), except that
thioglycollate was injected 1 h after intravenous administration of
control or anti-PECAM reagents. Measurements (animal weight;
peritoneal lavage volume, cell density, and differential count; pe-
ripheral blood count and smear; general autopsy) were performed 
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at 4, 18, or 24 h, as indicated in the figures. Representative sec-
tions of bowel and mesentery were submitted for histologic sec-
tions, which were stained with hematoxylin and eosin, and
scored in a blinded manner for leukocyte adhesion to the walls of
postcapillary venules as previously described (12).
 
Statistics.
 
The figures show representative experiments from
the many of each type performed. The bars give the mean 
 
6
 
standard error for five to six replicates of each variable tested. Since
the data involved nonparametric independent samples, statistical
significance was tested by the Mann-Whitney U test.
 
Results
 
PECAM-IgG Binds Homophilically to Endothelial Cell
PECAM.
 
The extracellular portion of PECAM is composed
of six immunoglobulin domains (6). Full-length PECAM-
IgG (i.e., domains 1–6 fused to IgG) and truncated versions
all migrated on SDS-PAGE at the appropriate relative mo-
lecular mass values for dimers of the expected size, and all
were recognized by CD31 mAb whose epitopes were in-
cluded in their sequence, but not by CD31 mAb with epi-
topes on domains not included in the constructs (reference 4
and data not shown.) Full-length PECAM-IgG bound sta-
bly enough to HUVEC to be detectable by FACScan
 
Ò
 
 anal-
ysis (Fig. 1). As had been demonstrated previously (24), this
binding represents homophilic adhesion to PECAM on the
HUVEC, since it was inhibitable by hec7 Fab, which binds
to PECAM domains 1 and/or 2, but not by mAb P1.2,
which binds to PECAM domain 6 or mAb 7E3 (25), a
blocking mAb against 
 
a
 
v
 
b
 
3
 
 (Fig. 1 
 
a
 
). Binding to mono-
cytes, which express an order of magnitude less PECAM
than HUVEC (26), was low (three times background; Fig.
1 
 
c
 
) to undetectable above background in seven separate
experiments with seven different blood donors.
In contrast, none of the truncated PECAM-IgG chi-
meric molecules could be detected bound to either mono-
cytes or endothelial cells by this method (Fig. 1), even at
concentrations that maximally inhibited transendothelial mi-
gration (see Fig. 2). This does not mean that PECAM-IgG
does not bind to the leukocyte PECAM. The off-rate of
these interactions is likely too fast for detectable levels to
remain bound after the multiple washings and incubations
of the FACS
 
Ò
 
 protocol (27).
 
Transendothelial Migration In Vitro Requires Domain 1 and/
or 2 of Endothelial Cell PECAM.
 
We tested the effects of
PECAM-IgG chimeras on the migration of Mo across
HUVEC monolayers. This system has been predictive of
results obtained in vivo. We consistently found that all
PECAM-IgG chimeras containing at least domain 1 blocked
TEM as well as the full-length molecule D1-6 IgG (Fig. 2).
The 60–80% block in TEM was equivalent to the block
obtained with hec7 mAb at 20 
 
m
 
g/ml (133 nM.) Several
important controls demonstrated that the inhibition of TEM
was due to the presence of the soluble PECAM molecule
and not an artifact of the human IgG tail (Fig. 2). (
 
a
 
) A chi-
meric protein consisting of an unrelated molecule, CD14,
fused to the same IgG tail, had no effect on TEM. (
 
b
 
) Solu-
ble PECAM chimeras were made in which either the en-
Figure 1. FACSÒ binding profiles of PECAM-IgG chimeras. Nonen-
zymatically resuspended HUVEC or PBMC were processed for FACScanÒ
analysis as described in Materials and Methods. The data of this figure are ar-
ranged in vertical columns. (a) PECAM-IgG binds homophilically to
PECAM on HUVEC. PECAM-IgG (100 nM) bound well to HUVEC.
When binding was carried out in the presence of 100 mg/ml Fab frag-
ments of anti-PECAM mAb hec7 (1hec7 Fab), binding was reduced to
control levels seen without any primary reagent. In contrast, 100 mg/ml Fab
fragments of mAb P1.2 (1P1.2 Fab), which binds to PECAM domain 6,
and has been shown not to be involved in homophilic adhesion or dia-
pedesis (4, 24), has no significant effect on PECAM-IgG binding. In addi-
tion, 7E3 (25), a blocking mAb against avb3, which has been reported to
be a heterophilic ligand for PECAM (39, 40) did not affect PECAM-IgG
binding to HUVEC (17E3). (b) Truncated PECAM-IgG chimeras do
not bind to HUVEC. While full-length PECAM-IgG (D1-6) bound well
to HUVEC, chimeras consisting of domain 1 (D1 IgG) or domains 1 and
2 (D112 IgG) of PECAM, or a full-length CD14 chimera (CD14 IgG)
did not bind significantly above background (Control). (c) When full-
length PECAM-IgG chimera (20 mg/ml, 100 nM) was incubated with
monocytes under the same conditions as for HUVEC, there was no sig-
nificant binding above background. (d) L cells transfected with murine
PECAM (20; mPECAM Transf.) were incubated with mAb 2H8 and de-
tected with a FITC-labeled goat anti–hamster mAb (1) or with full-
length mPECAM-IgG (mD1-6 IgG), murine domain 1-IgG (mD1 IgG),
or nonbinding human IgG (Control), washed, and then incubated with
FITC-labeled goat anti–human IgG. Only the mAb and full-length chi-
mera bind to the transfectants. (d, top) 2, mAb 2H8 binding to nontrans-
fected L cells. 
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tire extracellular portion of PECAM or only domains 1 and
2 were fused to the C
 
H
 
2 
 
1
 
 C
 
H
 
3 
 
1
 
 C
 
H
 
4 domains of IgM,
an immunoglobulin for which monocytes and HUVEC have
no receptors. These PECAM chimeras, produced in biva-
lent form by L cells (which lack the ability to make J chain),
blocked TEM as well as the PECAM-IgG did. (
 
c
 
) A form
of PECAM-IgG lacking domains 1 and 2 (D3-6 IgG) did
not block TEM. This last control also demonstrates the re-
quirement for the NH
 
2
 
-terminal domain(s) in this process.
Consistent with the hypothesis that soluble domain 1 is suf-
ficient to block TEM, D1 IgG and D1-2 IgG as well as full-
length PECAM-IgG blocked at all concentrations tested.
Some inhibition was seen at 5 nM, while maximum block-
ing was seen at 50 nM (Fig. 3).
When hec7 mAb was prebound to Mo in suspension
and the unbound antibody washed off, TEM was blocked
for at least an hour (Fig. 4, 
 
Preincubate with monocytes
 
, and refer-
ence 8). The same treatment performed with PECAM-IgG
at 100 nM (20 
 
m
 
g/ml), did not block TEM, consistent
with the inability of PECAM-IgG to bind stably to Mo
(Fig. 1). However, PECAM-IgG molecules did inhibit
TEM efficiently and in a long-lasting manner when they
were retained in the fluid surrounding the Mo (Fig. 2; Fig.
4, 
 
Added at t
 
0
 
). Taken together, these data suggest that the
low affinity interaction of PECAM-IgG chimeras with leu-
kocytes is capable of blocking TEM when sufficient local
concentration is maintained. No block in TEM was seen
when either mAb or PECAM-IgG were added to the api-
cal surface of the HUVEC monolayers for 1 h and then re-
moved before adding the monocytes (Fig. 4, 
 
Preincubate
with endothelium
 
). Additionally, PECAM-IgG did not block
TEM if preincubated separately with both monocytes and
endothelium before washing and combining (data not shown).
Because hec7 and D1-6 IgG would stably bind if they had
access to endothelial PECAM molecules in the junctions
(Fig. 1 and reference 8), it appears that the added reagents
were not effectively retained by the endothelial monolayer
Figure 2. Soluble domain 1 of PECAM is sufficient to block TEM.
Freshly isolated PBMC were suspended to 2 3 106/ml in medium M199
(M199), hec7 anti-PECAM mAb (20 mg/ml, 133 nM), or the indicated
purified PECAM-IgG constructs at a final concentration of 100 nM. D1
IgG indicates a chimeric molecule comprised of domain 1 of human PECAM
fused with the CH2 1 CH3 domains of human IgG1. D1-6 IgM indicates
a chimeric molecule comprised of full-length human PECAM fused with
the CH2 1 CH3 1 CH4 domains of human IgM. The cells were co-cul-
tured for 1 h at 378C to allow transendothelial migration, and the mono-
layers were then washed briefly in EGTA and DPBS before fixation and
quantitation of transmigration as described previously (4, 8). The data are
expressed as the mean 6 standard error of five replicates for each sample.
All chimeric proteins containing domain 1 of PECAM significantly
blocked transmigration. Asterisks (*) indicate P ,0.02. The results shown
are from a representative experiment of seven such experiments.
Figure 3. Domain 1-IgG blocks TEM as efficiently as full-length
PECAM-IgG or mAb hec7. Freshly isolated PBMC were resuspended
in the indicated concentrations of nonblocking binding control mAb W6/32
(anti–class I MHC), blocking anti-PECAM mAb hec7, or human PECAM-
IgG chimeras. The transmigration assay was carried out as in Fig. 2. For
the mAb 133 nM is z20 mg/ml; for full-length PECAM-IgG, 100 nM is
z20 mg/ml. The data shown are the mean and standard errors of three
experiments with six replicates per variable in each experiment. Asterisks
indicate P ,0.001 compared to W6/32.
Figure 4. PECAM-IgG chimeras interfere with leukocytes, not endo-
thelial cells in TEM. Freshly isolated PBMC were preincubated on ice for
30 min in hec7 mAb or PECAM domain 1-2 IgG or full-length PECAM-
IgG all at a final concentration of 100 nM (about 20 mg/ml by IgG
ELISA) before being washed free of unbound reagent, resuspended to 2 3
106/ml in M199, and added to HUVEC monolayers (Preincubate with
monocytes). Alternatively, the reagents were added to the apical surfaces of
HUVEC monolayers for 1 h at 378C before washing and adding un-
treated PBMC (Preincubate with endothelium). The third group of samples
consisted of the same PBMC resuspended to the same density in the same
concentrations of reagents and added together to untreated HUVEC
monolayers (Added at t0). Control PBMC were resuspended in M199
alone. Transmigration proceeded for 60 min. Data were quantitated as in
Fig. 2 as well as by evaluation of cross sections as described in Materials
and Methods. The data shown are the mean 6 standard error of six repli-
cates for each sample. Asterisks indicate P ,0.05. The experiment was
performed four times with similar results.1353 Liao et al.
(Fig. 4). Thus, the block mediated by either mAb or
PECAM-IgG added to the monocytes in suspension above
the HUVEC monolayer (Added at t0) must be due to inter-
action of the reagents with the monocytes. It then seems
reasonable to assume that PECAM-IgG is mimicking en-
dothelial PECAM in these interactions.
Domain 1 of Murine PECAM Blocks Inflammation In Vivo.
To test the relevance of the above studies to inflammation
in vivo, we produced murine PECAM-IgG chimeras in a
manner similar to the human PECAM-IgG chimeras (4). L
cells stably transfected with cDNAs encoding either the en-
tire extracellular portion of murine PECAM or domain 1
of murine PECAM fused to human IgG secreted the ap-
propriate sized proteins, which were reactive with antibod-
ies to both domain 1 of murine PECAM and human IgG
(data not shown). Analogous to the behavior of their hu-
man PECAM counterparts, full-length murine PECAM-
IgG (mD1-6 IgG) bound stably to transfectants bearing mu-
rine PECAM, whereas the chimera containing only murine
PECAM domain 1 did not (Fig. 1 d). These murine PECAM
fusion proteins (mPECAM-IgG) were tested for their abil-
ity to block leukocyte emigration in the thioglycollate
broth peritonitis model.
Figs. 5 and 6 show data from two experiments represen-
tative of five. The peritoneal cavities of unstimulated mice
contain negligible numbers of PMN. Thioglycollate in-
duced an acute inflammatory response in the peritoneal cavity
of these mice, which could be blocked by mPECAM-IgG
at both 4 and 24 h, reducing the numbers of emigrated
PMN to 47 and 25% of control, respectively. This inhibi-
tion was equivalent to that produced by optimal concentra-
tions of the blocking antimurine PECAM mAb 2H8 and
similar to that produced by anti-CD11b mAb 5C6, which
have been demonstrated to block in this model (12, 28) and
served as our positive controls (Fig. 5). A quantitatively
similar block has been produced in a rat model of acute
Figure 5. PECAM-IgG chimera blocks neutrophil emigration in vivo.
Female mice of the CD2F1 strain received a single injection via tail vein
(i.v.) of PBS, or 100 mg of either 2H8 anti–mouse PECAM mAb, 5C6
anti–mouse CD11b mAb, or murine PECAM-IgG chimera (mPECAM-
IgG) in a volume of 100 ml. 1 h later they received an intraperitoneal in-
jection (i.p.) of 1 ml of PBS or 4% thioglycollate broth (Thio). Mice were
killed at 4 h (light-shaded bars) or 24 h (dark-shaded bars) after intraperito-
neal injection. Peritoneal neutrophils were collected and enumerated.
The data are expressed as the mean and standard error of groups of three
mice. All treatment groups are significantly different from the PBS/Thio
group taken at the same time with a P value of ,0.05. Figure 6. Domain 1 of PECAM blocks leukocyte emigration in vivo.
Male mice of the FVB/N strain (five per group) received 100 mg of
CD14-IgG chimera as a negative control, a chimeric protein consisting of
domain 1 of murine PECAM (mD1 IgG), full-length murine PECAM
(mD1–6 IgG), or anti-CD11b (5C6) as a positive control 1 h before thi-
oglycollate injection. Mice were killed 18 h later and the concentration of
neutrophils (a) and Mo (b) in 5 ml of peritoneal lavage fluid was deter-
mined. Data are mean and standard error. All treatment groups are signif-
icantly different from the CD14-IgG with P ,0.05.1354 Soluble PECAM Domain 1 Blocks Transmigration
peritonitis using a cross-reacting rabbit anti–human PECAM
antibody (13).
Several experiments were performed in a different strain
of mice at 18 h after intraperitoneal injection to study the
effects of mPECAM-IgG chimeras on the influx of both
PMN and Mo. When human CD14-IgG was administered
intravenously before thioglycollate, there was no decrease
in PMN influx (Fig. 6), as expected from the in vitro stud-
ies. However, when either mPECAM domain 1-IgG or 1-6
IgG were administered (100 mg), the number of PMN re-
covered from the peritoneal cavity was reduced by z80%.
In four experiments, mPECAM domain 1-IgG blocked
PMN influx by 86 6 8%.
The unstimulated peritoneal cavity in the FVB/N strain
contains z5 3 105 mononuclear phagocytes/ml. In the ex-
periment shown in Fig. 6, the number of Mo recruited into
the peritoneal cavity had already risen to over 1.5 3 106/
ml (z8 3 106 total) by 18 h after thioglycollate stimulation
in mice that received the control fusion protein CD14-
IgG. In contrast, those mice treated with either full-length
or domain 1 mPECAM-IgG or mAb 5C6 had basal levels
of mononuclear phagocytes in their peritoneal cavities.
The number of circulating leukocytes was similar in all
experimental groups that received thioglycollate stimula-
tion (data not shown). Thus, the decrease in leukocytes en-
tering the peritoneal cavity was not due to their sequestra-
tion or destruction as a consequence of treatment.
Histologic sections of the peritoneal viscera of these mice
were examined. In the venules from mice treated with
mPECAM-IgG (both full-length and domain 1 only) a large
proportion of the leukocytes in the profile were noted to
be in apparent contact with the lumenal endothelium (Fig.
7, a–c). This was not seen in the venules of mice treated
with control CD14-IgG fusion protein nor anti-CD11b
mAb (Fig. 7, d and e).
Quantitation of these sections (see Materials and Meth-
ods) affirmed that blockade of inflammation with mPECAM-
IgG resulted in a significant increase in leukocytes in appar-
ent contact with the endothelium. Other treatments, both
blocking and nonblocking, were not associated with such
Figure 7. PECAM-IgG chimeras block leukocyte efflux at the venular lumenal surface. Representative photomicrographs from mesenteric venules of
the mice in the experiment depicted in Fig. 6. (a) Venule from mouse treated with domain 1 chimera showing multiple leukocytes (some indicated by ar-
rowheads) in apparent contact with the endothelial surface. The neutrophil at 12 o’clock is shown at higher magnification in the inset. Arrows point to en-
dothelial cell nuclei. (b) Image from another mouse treated with domain 1 construct showing a mononuclear cell (upper) and PMN (lower) in apparent
contact with the endothelial cell surface. (c) A similar image from mouse treated with full-length mPECAM-IgG with two PMN. In contrast, leukocytes
were only rarely seen attached to venules of mice treated with the nonblocking CD14-IgG chimera (d) or the adhesion blocking anti-CD11b mAb 5C6
(e). Bars: (a, d, and e) 50 mm; and (b and c) 20 mm.1355 Liao et al.
an increase (Fig. 8). This was found whether the data were
analyzed in terms of the percentage of intravascular leuko-
cytes in contact with the vascular lumen or in terms of the
percentage of venular profiles with more than one leuko-
cyte in contact.
Discussion
Our data provide the first evidence that a soluble mole-
cule corresponding to a fragment of a CAM, which is in-
capable of stable binding to its ligand, can nonetheless
block  inflammation. We show that PECAM domain 1-IgG
is sufficient to block the contribution of PECAM to trans-
endothelial migration of leukocytes. This truncated form of
PECAM is as efficient as a blocking mAb or full-length
PECAM-IgG at blocking TEM of monocytes in vitro and
of both neutrophils and monocytes in vivo. Furthermore, a
PECAM construct lacking domains 1 and 2 was without
effect. This demonstrates the importance of the NH2 ter-
minal domains of PECAM in these reactions.
PECAM-IgG Chimeric Proteins. Other investigators have
used chimeras of adhesion molecules fused with IgG to
study adhesive interactions in inflammation (29–32). The
bivalent nature of the molecules increases the binding affin-
ity, and the immunoglobulin chain prolongs the biological
half-life in vivo (33). While there are some well-known
examples involving selectins (29, 32, 34), there are few re-
ports on the use of CAMs from other molecular families
fused to IgG to block inflammation in vivo (33, 35). This
may be because most CAMs have a rather low affinity for
interaction with their ligands on a molecule-to-molecule
basis (27). Many immunoglobulin superfamily–Ig chimeras
only function when they are immobilized to a surface, al-
lowing multivalent interactions to occur (30, 31).
Full-length PECAM-IgG chimeras bind stably to HUVEC,
but not to Mo, which bear 10-fold less PECAM (26). Con-
sistent with this, high surface expression is apparently re-
quired for homophilic PECAM cell–cell adhesion (refer-
ence 36 and our unpublished data). Truncated forms of
PECAM do not bind stably enough even to HUVEC to be
detected by FACSÒ (Fig. 1). Sun et al. (24) demonstrated
that domains 1 and 2 were necessary for homophilic bind-
ing under these conditions. They are sufficient to mediate
homophilic binding, but only when expressed on a full-
length Ig superfamily backbone. Fawcett et al. also found
that only full-length PECAM molecules supported stable
adhesion (37).
Several controls demonstrated that the effects we ob-
served with our PECAM-IgG chimeras were not due to
the interaction of the IgG portion of the molecule with
leukocyte Fc receptors; a full-length CD14 molecule and
the PECAM domain 3–6 construct had no effect on TEM
when fused to the same IgG molecule. On the other hand,
both full-length and domain 1 1 2 of PECAM fused to the
human IgM COOH tail blocked TEM. Furthermore, no
Fc-mediated binding of the truncated PECAM-IgGs or the
CD14-IgG to monocytes was detected by FACScanÒ (Fig.
1). There was no evidence that infusion of murine PECAM-
IgG chimeras resulted in opsonization of leukocytes, con-
sistent with previous experience using other CAM-IgG
chimeras in vivo (29, 34). For therapeutic purposes, Fc-
mediated interactions could be further precluded by design
of a chimera with the opsonic portions of the Fc chain de-
leted (38).
Identifying the Domains of PECAM Used by Endothelial
Cells. As expected from previous studies using mAbs (8),
no block in TEM was seen when either mAb or PECAM-
IgG were added to the apical surface of the HUVEC
monolayers for 1 h before washing the monolayer surface
(Fig. 4). Since both hec7 mAb and D1-6 IgG are capable of
binding tightly to endothelial PECAM, this observation
suggests that these reagents were not accessible to PECAM
sequestered in the junctions of the endothelial monolayer.
Therefore, the block mediated by these reagents when
added to the monocytes in suspension above the HUVEC
monolayer must be due to interaction of the reagents with
the monocytes. If we then reasonably assume that PECAM-
IgG, including D1-IgG, is mimicking endothelial PECAM
in these interactions, these data provide evidence that do-
main 1 and/or 2 are crucial for the role of endothelial cell
PECAM in transmigration.
Since we have previously demonstrated that domains 1
and/or 2 of monocyte PECAM are required for TEM (4),
it seems most likely that domain 1 and/or 2 on both leuko-
cyte and endothelial PECAM interact with each other in a
homophilic manner during TEM. In support of this, the
effects of blocking these domains on both the endothelial
cell and the Mo simultaneously, are not additive (reference
8 and data not shown).
Figure 8. PECAM-IgG chimeras lead to increase in apparent contact
of leukocytes with venule wall. The first 10 venules of appropriate size for
each of the mice in the experiment of Fig. 7 were scored in a blinded
fashion for leukocytes free within the lumen and those in apparent con-
tact with the venular wall. Data are expressed as the percent of total leu-
kocytes adherent to the wall (top) or the percent of vascular profiles with
more than one attached leukocyte (bottom). The data are expressed as the
mean and standard error for all mice in the group. Asterisks indicate that
data are significantly different from any of the other groups with a P ,0.025.
Reagent, the intravenous treatment; Thio, whether or not mice received
intraperitoneal injection of thioglycollate (1) or PBS (2).1356 Soluble PECAM Domain 1 Blocks Transmigration
The Site of PECAM Blockade. The block in TEM ob-
tained with PECAM-IgGs both in vitro and in vivo resem-
bles the block obtained with mAbs against PECAM both
quantitatively and qualitatively. In our culture system, Mo
were seen to be tightly bound to the apical surface of
HUVEC monolayers over the junctions as in reference 8,
while in the murine venules in the inflamed mesentery
showed leukocytes in contact with the endothelial cell lin-
ing, as if arrested before diapedesis (Figs. 7 and 8), as we had
previously seen with mAb 2H8 (12). It is notable that the
epitope for mAb 2H8 is in domain 1 of murine PECAM.
Thus, soluble domain 1 of PECAM, which is incapable
of high affinity binding to cellular PECAM, can mimic the
effects of a blocking antibody without the potential com-
plications associated with immune complex formation. This
work defines domain 1 of PECAM as a target for therapeu-
tic intervention.
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